基于卡盒的检测法提升痰标本中耐多药结核分枝杆菌的检出
研究开发了可在10色GeneXpert仪器上运行的自动化核酸扩增检测MDRmDx,可直接从痰标本中检测MTB、RIF-R(含RRDR及I491F突变)和INH-R(katG、fabG1、inhA启动子突变)。分析研究中MTB LoD为21.6 CFU/mL,RIF-S LoD为108.8 CFU/mL,INH-S LoD为92.2 CFU/mL;冰冻富集痰标本中MTB灵敏度91.3%、RIF-R灵敏度100%、INH-R灵敏度98.7%,性能与Ultra相当。
要点
- MDRmDx可检测Ultra漏检的rpoB I491F等RIF-R突变。
- MDRmDx可同时检测INH-R相关katG、fabG1和inhA启动子突变。
- 痰标本检测MTB、RIF-R、INH-R的灵敏度和特异性与Ultra相当。
核心结论
- MDRmDx检测MTB、RIF-R和INH-R的性能至少与Ultra相当,并额外检测INH-R和rpoB I491F突变。
研究设计与样本
- 分析研究评估MDRmDx的LoD及突变检出能力,并用冰冻富集痰标本(富集涂阴、RIF-R和INH-R样本)进行回顾性检测。
主要发现
- 痰标本MTB LoD为21.6 CFU/mL(95%CI 14.9-28.3),Ultra为19.1 CFU/mL(95%CI 14.0-24.1)。
- RIF-S LoD为108.8 CFU/mL(95%CI 77.4-140.2),Ultra为100.9 CFU/mL(95%CI 67.3-134.5)。
- INH-S LoD为92.2 CFU/mL(95%CI 65.3-119.1)。
- MDRmDx可检出所有全球流行率≥0.5%的rpoB突变,包括Ultra未检出的突变,特异性100%。
- 冰冻富集痰标本中MTB灵敏度91.3%(95%CI 85.6-94.8)、RIF-R灵敏度100%(95%CI 95.1-100)、INH-R灵敏度98.7%(95%CI 93.0-99.8);MTB特异性98.0%(95%CI 89.3-99.6)、RIF-R特异性93.8%(95%CI 83.2-97.9)、INH-R特异性100%(95%CI 90.8-100)。
临床怎么用
- MDRmDx可在10色GeneXpert仪器上直接检测痰标本,同步报告MTB、RIF-R和INH-R。
- 相比Ultra,MDRmDx额外覆盖INH-R和rpoB I491F等RIF-R突变,有助于耐药结核的检出和有效治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Tuberculosis (TB) is a global health threat complicated by increasing INH resistance (INH-R) and rifampicin resistance (RIF-R), including RIF-R due to rpoB Ile491Phe (I491F) mutations, which are not detected by current molecular resistance tests. We developed a low-complexity automated nucleic acid amplification test MDRmDx, designed to operate on the 10-color GeneXpert instrument, which detects Mycobacterium tuberculosis (MTB), and RIF-R in both the rifampicin resistance determining region (RRDR) and the I491F allele, and INH-R due to mutations in katG, fabG1, and the inhA promoter directly from sputum. In an analytic study, the limit of detection (LoD) for detecting MTB in sputum was 21.6 CFU/mL (95% confidence interval [CI]: 14.9-28.3) for the MDRmDx assay, versus 19.1 CFU/mL (95% CI: 14.0-24.1) for the Xpert MTB/RIF Ultra assay (Ultra). The LoD for rifampicin susceptibility (RIF-S) detection was 108.8 CFU/mL (95% CI: 77.4-140.2) versus 100.9 CFU/mL (95% CI: 67.3-134.5) for MDRmDx versus Ultra. The LoD for INH susceptibility detection was 92.2 CFU/mL (95% CI: 65.3-119.1). MDRmDx identified all rpoB mutations with a ≥0.5% global prevalence, including several not detected by Ultra. MDRmDx was 100% specific. Testing frozen sputum enriched for smear-negative, RIF-R, and INH-R samples, MDRmDx sensitivity was 91.3% (95% CI: 85.6-94.8) for MTB detection, 100% (95% CI: 95.1-100) for RIF resistance, and 98.7% (95% CI: 93.0-99.8) for INH resistance, with a specificity of 98.0% (95% CI: 89.3-99.6) for MTB detection, 93.8% (95% CI: 83.2-97.9) for RIF resistance, performance comparable to Ultra. MDRmDx specificity for INH-R was 100% (95% CI: 90.8-100). IMPORTANCE: The Xpert MTB/RIF Ultra assay (Ultra) is a gold standard test for rapidly diagnosing tuberculosis (TB) as well as resistance to rifampicin directly from sputum samples. However, the Ultra assay does not detect certain rifampicin resistance mutations, which are observed clinically and cannot detect resistance to isoniazid, another key drug against TB. We modified the Ultra assay, creating a prototype MDRmDx assay designed for 10-color instruments that detects isoniazid resistance, which can be a precursor of potential rifampicin resistance and has improved ability to detect rifampicin resistance. In both analytic and retrospectively collected clinical sputum samples, we found that the MDRmDx assay performed at least as well as the Ultra assay with the additional advantage of detecting isoniazid resistance and rpoB I491F mutations with high sensitivity and specificity. The MDRmDx assay's improved performance should improve detection of drug-resistant TB and facilitate the selection of effective treatment.
引用
- Rudra P, Parmar H, Daivaa N, et al. A cartridge-based assay for improved detection of multidrug-resistant Mycobacterium tuberculosis directly from sputum. J Clin Microbiol. 2026. PMID: 41910325. doi:10.1128/jcm.01100-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。